Venture capital firm Essex Woodlands Health Ventures led the $45m round for Revance Therapeutics, which also included CNF Investments and others.
Revance Therapeutics, a US-based beauty company, has raised $45m from a consortium including CNF Investments, the $225m corporate venturing unit of Clark Enterprises, as a new investor.
Venture capital firm Essex Woodlands Health Ventures led the round, which also included peers NovaQuest Capital after its independence from drugs group Quintiles in November, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors and Pac-Link Ventures.
Jonathan Tunnicliffe, a partner at NovaQuest, will join Revance’s board and said: "The market for botulinum…
